|
|
||||||||
BRIEF COMMUNICATION |
Institutes of Medicine and Nuclear Chemistry, Research Center Jülich, Jülich; and Clinics of Nuclear Medicine and Urology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
Tumor uptake of the amino acid cis-4-[18F]fluoro-L-proline (cis-FPro) was studied with PET in eight patients with urologic tumors. Methods: Three patients had primary renal cell carcinomas (RCCs), one had a local recurrence of RCC, one had squamous RCC, one had an adrenal hemangioma, one had inguinal metastases of penile squamous carcinoma, and one had suspected metastatic disease from prostate cancer. PET scans of the trunk were acquired at 1 and 35 h after intravenous injection of 400 MBq cis-FPro and compared with 18F-FDG PET scans and CT. Results: None of the tumors or metastases showed significant uptake of cis-FPro. FDG uptake was seen in one of the three primary RCCs, in the local recurrence of RCC, in the squamous RCC, and in the metastases of penile cancer. Conclusion: Cis-FPro appears not to be a promising PET tracer in oncology.
Key Words: cis-4-[18F]fluoro-L-proline radiolabeled amino acids renal tumors PET
This article has been cited by other articles:
![]() |
K.-J. Langen, D. Salber, K. Hamacher, G. Stoffels, G. Reifenberger, D. Pauleit, H. H. Coenen, and K. Zilles Detection of Secondary Thalamic Degeneration After Cortical Infarction Using cis-4-18F-Fluoro- D-Proline J. Nucl. Med., September 1, 2007; 48(9): 1482 - 1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Scher, M. Seitz, M. Reiser, E. Hungerhuber, K. Hahn, R. Tiling, P. Herzog, M. Reiser, P. Schneede, and S. Dresel 18F-FDG PET/CT for Staging of Penile Cancer J. Nucl. Med., September 1, 2005; 46(9): 1460 - 1465. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |